Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Dcol Center for Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$3,366,476

1,487 payments

Through program year 2025, Dcol Center for Clinical Research is reported as receiving $3,366,476 in research payments, across 1,487 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $248,583 118
2024 Research $430,304 145
2023 Research $1,038,978 752
2022 Research $344,568 246
2021 Research $793,483 17
2020 Research $399,712 143
2019 Research $110,848 66

Breakdown

Who paid Research payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $2,235,787 210 payments
  2. Novo Nordisk AS $817,126 1,114 payments
  3. Boehringer Ingelheim International GmbH $105,209 103 payments
  4. AbbVie, Inc. $88,697 18 payments
  5. Gilead Sciences, Inc. $56,031 22 payments
  6. Boehringer Ingelheim Pharma GmbH & Co.KG $46,525 10 payments
  7. GlaxoSmithKline, LLC. $15,396 8 payments
  8. Pfizer Inc. $1,280 1 payment
  9. AstraZeneca Pharmaceuticals LP $424 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Nn9536-4999 $605,185 534 payments
  2. A Phase 3, Randomized, Active-Controlled, Double-blind Clinical Study to Evaluate a Switch to Doravirine,Islatravir DOR,ISL Once-Daily in Participants With HIV-1 Virologically Suppressed on Bictegravir,Emtricitabine,Tenofovir Alafenamide BIC,FTC,TAF $530,720 41 payments
  3. A Phase 3 Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Adults 18 to 49 Years of Age $389,489 7 payments
  4. A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine na Adults $306,672 6 payments
  5. A Phase 2b, Randomized, Active-Controlled, Double-Blind, Dose-Ranging Clinical Study to Evaluate a Switch to Islatravir ISL and MK-8507 Once-Weekly in Adults with HIV-1 Virologically Suppressed on Bictegravir,Emtricitabine,Tenofovir Alafenamide BIC,FTC,TAF Once-Daily $287,033 4 payments
  6. Nn9536-7545 $211,942 580 payments
  7. A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED $208,108 29 payments
  8. A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate a Switch to Doravirine,Islatravir DOR,ISL 100 mg,0.25 mg Once-Daily in Participants With HIV-1 Who Are Virologically Suppressed on Bictegravir,Emtricitabine,Tenofovir Alafenamide BIC,FTC,TAF $136,960 2 payments
  9. A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants $131,219 12 payments
  10. EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) $114,251 102 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record